ChondroFiller as an outpatient hip injection

ChondroFiller is an injection — not an operation. Patients sometimes arrive expecting a theatre booking, but the treatment takes place in an outpatient clinic under ultrasound guidance, with no incisions, no general anaesthetic, and no surgical wound to recover from.

The product itself is a CE-marked Class III medical device: an acellular, injectable Type I collagen scaffold that gels in place once it reaches the hip joint. The mechanism is known as acellular matrix-induced chondrogenesis. Rather than implanting live cells, the scaffold creates a structured collagen matrix that recruits the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — which then migrate in and begin the body's own repair process over the following weeks and months.

Within the hip joint, ChondroFiller acts as a top-down, additive collagen cushion laid over degenerated articular surfaces. This is distinct from older bottom-up techniques that require surgical debridement of the lesion bed; here, the existing joint environment and fluid are preserved, and the collagen is placed directly over the worn area under image guidance.

The treatment is indicated for focal, isolated Grade III/IV hip cartilage defects and for patients with Kellgren-Lawrence Grade III/IV hip osteoarthritis who are not ready or suitable for joint replacement. Because delivery takes place in a fluid joint — rather than a surgically dried field — the hip is well suited to this injectable approach.

Lincolnshire Hip offers this pathway as an ultrasound-guided outpatient injectable scaffold treatment, accessible without a surgical referral.

How hip outcomes are measured: Harris Hip Score and MOCART

Two distinct instruments are used to track what ChondroFiller does in the hip — one asks how the patient feels, the other looks directly inside the joint.

The Harris Hip Score (HHS) is the standard patient-centred measure for hip interventions. Introduced by William H. Harris in 1969, it runs from 0 to 100 across four domains: pain, function, range of movement, and deformity. A score of 80 or above is the accepted threshold for a good-to-excellent result — in practical terms, this means a patient can manage stairs, walk reasonable distances, and carry out daily activities without significant limitation. Scores below 70 indicate poor function. The HHS has been the clinical benchmark for hip treatments for over five decades and is the appropriate framework for reporting ChondroFiller hip outcomes.

The MOCART score (Magnetic Resonance Observation of Cartilage Repair Tissue) provides the structural counterpart. It is an MRI-based tool that evaluates whether repair tissue is filling the defect to the correct depth, whether the surface is congruous with the surrounding cartilage, how well the new tissue integrates at its borders, and whether the signal intensity on MRI is approaching that of healthy hyaline cartilage. Scores are reported on a 0–100 scale; values above 80 indicate that more than 80% of the defect has been filled with well-integrated tissue.

A simple way to hold both instruments together: the HHS tells us how the hip feels; MOCART tells us what the hip looks like. Neither alone is sufficient — a patient can report improved symptoms before the repair tissue has fully matured, and vice versa.

For whole-joint hip assessment in advanced osteoarthritis, the SHOMRI (Scoring Hip Osteoarthritis with MRI) system evaluates all compartments simultaneously. MOCART remains the appropriate tool for focal post-repair tissue assessment, which is why it features in ChondroFiller clinical follow-up.

MOCART MRI scores: what the structural imaging shows

Structural MRI data provides the clearest independent signal of what happens inside the hip joint after a ChondroFiller injection, and the findings from European clinical studies are consistent: MOCART scores range from 81.6 to 84.3, indicating that more than 80% of the treated cartilage defect has been filled with repair tissue that integrates well with the surrounding native cartilage.

The time-course data is arguably more informative than any single endpoint figure. In one key study, the mean MOCART score stood at 65.3 just four weeks after treatment — reflecting early scaffold consolidation rather than mature repair tissue. By twelve months, that figure had risen to 81.6. This is a clinically important pattern: the hip joint continues maturing its repair tissue well beyond the initial injection, which is why both imaging and functional assessments should be interpreted within a timeframe that allows for that biological process.

MOCART evaluates repair tissue across five parameters — defect fill depth, surface congruity, border integration, signal intensity, and subchondral bone status — and these criteria apply uniformly regardless of which joint is being imaged. A MOCART assessment of hip cartilage repair tissue uses exactly the same structural lens as one applied after treatment of another joint, which means the European multi-joint data is directly applicable to the hip context.

These figures come from post-market studies covering multiple joints in which the hip is among the indicated anatomical sites. That context supports rather than weakens the interpretation: MOCART scores consistently reaching above 80 reflect a biological repair tissue response that the evidence shows is reproducible across joints — and that includes the hip.

Functional improvement: what clinical scores indicate for hip patients

A mean improvement of approximately 30 points on the modified Harris Hip Score (mHHS) is the functional benchmark that ChondroFiller hip injection data points towards — and its clinical weight becomes clear once it is mapped to the scoring scale.

The HHS runs from 0 to 100, with 80 marking the threshold for good-to-excellent hip function. A patient presenting with moderate hip osteoarthritis typically scores in the 50–55 range: enough to manage light daily activity but limited on stairs, longer walking distances, and rising from low chairs. A 30-point gain from that starting point reaches 80–85 — in practical terms, a recovery of precisely the functions that are most disabling day to day.

This 30-point figure is comparable in magnitude to the IKDC improvements documented across four post-market clinical follow-up (PMCF) studies summarised in the Version 09 Clinical Evaluation Report (CER, April 2025). Across those studies, mean functional gains of approximately 30 points consistently exceeded the established minimum clinically important difference (MCID) of 16.7 points for comparable patient-reported hip outcome tools — confirming that the change is clinically meaningful, not merely a statistical shift. The mHHS benchmark for the hip reflects the same order of magnitude.

The most durable functional evidence comes from the Jerosch et al. prospective PMCF study, which recorded a mean endpoint score of 80 at three-year follow-up. Patients reached the good-to-excellent band and remained there — a signal of sustained benefit rather than a treatment effect that diminishes over the first year.

The 30-point mHHS figure is derived from multi-joint clinical data — that is its evidential basis when applied to the hip. No isolated hip trial reporting granular mHHS change scores as a primary endpoint has been published in the peer-reviewed literature to date; what that means clinically is that the hip-specific figure rests on the CER rather than a dedicated hip cohort. The CER explicitly covers the hip among its indicated joints, and the functional gains it documents share the same mechanism and approximate scale across the anatomical sites studied.

Safety profile and how it compares to surgical alternatives

For patients weighing whether to pursue injection treatment or proceed to surgery, the safety record of ChondroFiller across reviewed clinical studies is a material consideration.

Across the post-market clinical follow-up cohorts summarised in the Version 09 Clinical Evaluation Report (April 2025), the complication rate attributable to the injectable collagen scaffold is approximately 0% — no serious adverse events were recorded in the reviewed studies. The reoperation rate across studies is approximately 3–8%. Those figures compare favourably with the surgical alternatives: microfracture carries a reoperation rate of up to 41%, while ACI and MACI procedures are associated with complication rates of up to 17%. Both are operating-theatre procedures requiring general or spinal anaesthesia — risks that the outpatient injection pathway avoids entirely.

For patients with Kellgren-Lawrence Grade III/IV hip osteoarthritis who are not yet suitable for hip replacement, or who wish to preserve the joint for as long as possible, this profile positions ChondroFiller as a low-risk, joint-preserving option within a well-established hip injection pathway.

Two caveats apply. First, no treatment is without risk — individual suitability, existing health factors, and joint-specific findings should be discussed with a hip specialist before any intervention. Second, the published follow-up horizon currently extends to three years; longer-term hip-specific safety data remain to be established.

Who is suitable and how to access assessment

Deciding whether ChondroFiller hip injection is appropriate starts with an honest look at where the hip is in its disease trajectory.

The injection is best suited to patients with focal Grade III/IV cartilage defects or Kellgren-Lawrence Grade III/IV hip osteoarthritis who retain sufficient joint architecture — meaning the femoral head and acetabulum still hold reasonable congruency. It is not a substitute for hip replacement where the joint has already collapsed. Patients who have not gained adequate benefit from physiotherapy or hyaluronic acid injections, or who wish to delay or avoid surgery while the joint remains preservable, are the primary candidates.

Before the injection, a structured baseline matters: clinical Harris Hip Score recording and hip MRI — using MOCART criteria for any focal repair site — provide a reference point against which improvement can be meaningfully measured at follow-up. This approach turns the assessment into an ongoing clinical narrative rather than a one-off procedure.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment at Sleaford and Grantham. A hip specialist appointment — covering clinical examination, imaging review, and a full discussion of the injection and surgical pathway options — is the appropriate starting point for anyone considering this route.

1. [1] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
2. [2] Harris Hip Score. https://en.wikipedia.org/?curid=42774279 https://en.wikipedia.org/?curid=42774279